Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension

N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Diuretics / therapeutic use
  • Drug Therapy, Combination
  • Dyspnea / etiology
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors*
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Practice Guidelines as Topic
  • Purines / adverse effects
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfones / adverse effects
  • Sulfones / therapeutic use*
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Diuretics
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Warfarin
  • Sildenafil Citrate